67298
强的松
pharmaceutical secondary standard; traceable to USP, PhEur and BP
别名:
1-可的松, 17Α,21-二羟基-1,4-孕甾二烯-3,11,20-三酮, 去氢可的松, 强的松
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H26O5
化学文摘社编号:
分子量:
358.43
EC Number:
200-160-3
UNSPSC Code:
41116107
PubChem Substance ID:
Beilstein/REAXYS Number:
2065301
MDL number:
InChI key
XOFYZVNMUHMLCC-ZPOLXVRWSA-N
InChI
1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
SMILES string
O=C1C=C[C@@]2(C)C(CC[C@]([C@@](CC[C@@]3(C(CO)=O)O)([H])[C@]3(C)C4)([H])[C@]2([H])C4=O)=C1
grade
certified reference material, pharmaceutical secondary standard
agency
traceable to BP 553, traceable to Ph. Eur. P2900000, traceable to USP 1559006
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
mp
236-238 °C (lit.)
format
neat
Gene Information
human ... NR3C1(2908)
正在寻找类似产品? 访问 产品对比指南
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
O Teuffel et al.
Leukemia, 25(8), 1232-1238 (2011-04-30)
This systematic review and meta-analysis compared the efficacy and toxicity of dexamethasone (DEX) versus prednisone (PRED) for induction therapy in childhood acute lymphoblastic leukemia (ALL). We searched biomedical literature databases and conference proceedings for randomized controlled trials comparing DEX and
Ronald de Wit
European journal of cancer (Oxford, England : 1990), 41(4), 502-507 (2005-03-02)
Until now, the use of systemic chemotherapy for advanced androgen-independent prostate cancer has had very little to offer to patients. However, in 2004, two large randomised trials investigating docetaxel vs. mitoxantrone have both demonstrated survival improvements, and, in one of
A Palumbo et al.
Annals of hematology, 89(8), 803-811 (2010-03-17)
Thalidomide has received approval from the European Agency for the Evaluation of Medicinal Products for the treatment of newly diagnosed multiple myeloma (MM) patients older than 65 years or ineligible for transplant. The results of five phase III trials assessing
Charles J Ryan et al.
The Lancet. Oncology, 16(2), 152-160 (2015-01-21)
Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysis of the trial, assessing
Ian F Tannock et al.
The Lancet. Oncology, 14(8), 760-768 (2013-06-08)
Docetaxel plus prednisone is standard first-line chemotherapy for men with metastatic castrate-resistant prostate cancer. Aflibercept is a recombinant human fusion protein that binds A and B isoforms of VEGF and placental growth factor, thereby inhibiting angiogenesis. We assessed whether the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持